Vernakalant hydrochloride: Antiarrhythmic drug dual sodium/potassium channel blocker

Drugs of the Future

Volumn 32, Issue 3, 2007, Pages 234-244

  Revill, P ^a   Serradell, N ^a   Bolos J ^a   Rosa, E ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DOFETILIDE; ION CHANNEL; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; RSD 1235; SOTALOL; UNCLASSIFIED DRUG; VERNAKALANT HYDROCHLORIDE;

AORTA STENOSIS; ARTICLE; CELL STRAIN HEK293; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM CONTRACTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; LOW DRUG DOSE; MUSCLE CELL; NONHUMAN; P WAVE; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SINUS RHYTHM; SNEEZING; STROKE; TASTE DISORDER; TORSADE DES POINTES;

EID: 34250361986     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.03.1084809     Document Type: Article

References (47)

1. Beatch, G.N., Choi, L.S.L., Jung, G. et al. (Cardiome Pharma Corp.). Aminocyclohexyl ether compounds and uses thereof. EP 1560812, EP1666459, JP 2006525227, WO 2004099137.
2. Plouvier, B.M.C., Chou, D.T.H., Jung, G. et al. (Cardiome Pharma Corp.). Synthetic process for aminocyclohexyl ether compounds. WO 2006088525.
3. Machiya, K., Ike, K., Watanabe, M., Yoshino, T., Okamoto, T., Morinaga, Y., Mizobata, S. (Astellas Pharma, Inc.). Production method of optically active cyclohexane ether compounds. WO 2006075778.
4. Roth, C.J., Jung, G., Plouvier, B.M.C., Chou, D.T.H., Yee, J.G.K. (Cardiome Pharma Corp.). Synthetic processes for the preparation of aminocyclohexyl ether compounds. WO 2006138673.
5. Balkenhohl, F., Ditrich, K., Nübling, C. (BASF AG). Racemate separation of primary and secondary heteroatom-substituted amine by enzyme-catalysed acylation. WO 9623894.
6. Go, A.S. The epidemiology of atrial fibrillation in elderly persons: The tip of the iceberg. Am J Geriatr Cardiol 2005, 14(2): 56-61
7. Lloyd-Jones, D.M., Wang, T.J., Leip, E.P. et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004, 110(9): 1042-6.
8. Wolf, P.A., Abbott, R.D., Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22(8): 983-8.
9. Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.W., Selby, J.V., Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA - J Am Med Assoc 2001, 285(18): 2370-5.
10. Kannel, W.B., Wolf, P.A., Benjamin, E.J., Levy, D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998, 82(8A): 2N-9N.
11. Yuan, Z., Bowlin, S., Einstadter, D., Cebul, R.D., Conners, A.R. Jr., Rimm, A.A. Atrial fibrillation as a risk factor for stroke: A retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health 1998, 88(3): 395-400.
12. Page, R.L., Roden, D.M. Drug therapy for atrial fibrillation: Where do we go from here? Nat Rev Drug Discov 2005, 4(11): 899-910.
13. Cardiome and Astellas announce acceptance of NDA for review. Cardiome Pharma Press Release, February 19, 2007.
14. Fedida, D., Orth, P.M., Chen, J.Y.C. et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005, 16(11): 1227-38.
15. Beatch, G.N., Lin, S.-P., Hesketh, C., Johnson, B.D., Ezrin, A.M., Fedida, D. Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug. Circulation 2003, 108(17, Suppl. 4): Abst 400.
16. Wang, Z., Gibson, J.K., Ezrin, A., Fedida, D. The molecular basis of high-affinity binding of the anti-arrhythmic compound, RSD1235, to the α-subunit of Kv1.5 channels. Circulation 2006, 114(18, Suppl. 2): Abst 929.
17. Na and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol 2006, 17(Suppl. 1):S71-8.
18. Na and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006, 70(3): 486-96.
19. + current active during repolarization. Biophys J 2004, 86: Abst 706.
20. Hesketh, J.C., Beatch, G.N., Ezrin, A.M., Johnson, B.D., Fedida, D. Safety of RSD1235 in a rabbit Purkinje fiber model. Pharmacologist 2002, 44(2, Suppl. 1): Abst 22.12.
21. Orth, P.M., Lynn, L.M., Yang, Y. et al. The novel AF conversion agent RSD1235 terminates EADs and prevents torsade de pointes in a rabbit model. Circulation 2004, 110(17, Suppl. 3): Abst 3433.
22. Nattel, S., De Blasio, E., Beatch, G.N., Wang, W.-Q. RSD1235: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Eur Heart J 2001, 22(Suppl.): Abst P2362.
23. Beatch, G.N., Shinagawa, K., Johnson, B.D. et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodelled atria. Pharmacologist 2002, 44(2, Suppl. 1): Abst 22.11.
24. Beatch, G.N., Helmes, M., Blaauw, Y., Allessie, M.A. Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atrial-selective antiarrhythmic drug, RSD1235, in the goat. Circulation 2004, 110(17, Suppl. 3): Abst 778.
25. Beatch, G.N., Grant, S., Clohs, L., Ezrin, A.M. RSD1235, a novel atrial-selective antiarrhythmic drug, shows rapid and extensive oral absorption in man. Cardiovasc Drug Ther 2003, 17(5-6): Abst P1.
26. Cardiome reports additional phase 1 trial data for oral RSD1235. Cardiome Pharma Press Release, May 5, 2006.
27. Ezrin, A.M., Grant, S., Bell, G. et al. Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Cardiovasc Drug Ther 2002, 16(Suppl.): Abst P297.
28. Ezrin, A.M., Grant, S.M., Bell, G. et al. A dose-ranging study of RSD1235, a novel antiarrhythmic agent, in healthy volunteers. Pharmacologist 2002, 44(2, Suppl. 1): Abst 22.10.
29. Dorian, P., Mangat, I., Korley, V., Beatch, G.N., Cvitkovic, S., Pinter, A. Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Circulation 2004, 110(17, Suppl. 3): Abst 2172.
30. Dorian, P., Mangat, I., Korley, V., Beatch, G.N., Cvitkovic, S., Pinter, A. The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. Can J Cardiol 2005, 21(Suppl. C): Abst 744.
31. Dorian, P., Mangat, I., Korley, V., Beatch, G.N., Cvitkovic, S., Pinter, A. The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. Circulation 2005, 112(17, Suppl. 2): Abst 2369.
32. Roy, D., Rowe, B.H., Stiell, I.G. et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004, 44(12): 2355-61.
33. Roy, D., Rowe, B.H., Stiell, I.G. et al. A randomized controlled trial of a novel antiarrhythmic agent, RSD1235, in the treatment of acute atrial fibrillation. Acad Emerg Med 2003, 10(5): 423-4.
34. Roy, D., Beatch, G.N., Steill, I. et al. RSD1235 rapidly and effectively terminates atrial fibrillation. Eur Heart J 2003, 24(Suppl.): Abst 3699.
35. Roy, D., Pratt, C., Wyse, D.G., Toft, E., Torp-Pederson, C., Juul-Moller, S. RSD1235 for conversion of atrial fibrillation. The phase III Atrial arrhythmia Conversion Trial. Can J Cardiol 2005, 21(Suppl. C): Abst 737.
36. Roy, D., Pratt, C., Wyse, D.G., Toft, E., Torp-Pederson, C., Juul-Moller, S. Efficacy and safety of RSD1235 in the treatment of recent onset atrial fibrillation in ACT I (Atrial arrhythmia Conversion Trial I), a phase III, randomised, placebo-controlled, multi-center trial. Eur Heart J 2005, 26(Suppl. 1): Abst P3045.
37. Pratt, C., Roy, D., Juul-Moller, S., Torp-Pedersen, C., Toft, E., Nielsen, T. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo-controlled, multicenter trial. 15th World Congr Cardiac Electrophysiol Cardiac Tech (June 14-17, Nice) 2006, Abst 155/3.
38. Roy, D., Pratt, C., Juul-Moller, S., Toft, E., Wyse, D.G., Nielsen, T., Rasmussen, S.L. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo-controlled, multicenter trial. J Am Coll Cardiol 2006, 47(4, Suppl. 1): Abst 804-3.
39. Study to determine the response and effectiveness of RSD1235 in subjects with atrial fibrillation or atrial flutter (NCT00115791). ClinicalTrials.gov Web site, February 15, 2007.
40. Torp-Pederson, C., Roy, D., Pratt, C. et al. Efficacy and safety of RSD1235 injection in the treatment of atrial fibrillation: Combined analysis of two phase III trials. Eur Heart J 2006, 27(Abstract Suppl.): 887.
41. Roy, D., Pratt, C., Camm, J. et al. RSD1235 effectively converts atrial fibrillation to sinus rhythm independent of background use of oral rate- or rhythm-control medications. Circulation 2006, 114(18, Suppl. 2): Abst 3697.
42. Vidaillet, H., Kitt, T.M., Dickinson, G., Mangal, B. Vernakalant (RSD1235) injection converts recent-onset atrial fibrillation to sinus rhythm rapidly and effectively. Crit Care Med 2006, 34(12, Suppl.): Abst 208.
43. Steill, I., Roy, D., Rowe, B.H., Pratt, C., Dickinson, G., Kitt, T. Efficacy and safety of RSD1235 in the treatment of acute atrial fibrillation. Acad Emerg Med 2006, 13(5, Suppl. 1): Abst S162.
44. Response to RSD1235 compared to placebo in subjects with atrial arrhythmia after heart surgery (NCT00125320). ClinicalTrials.gov Web site, February 15, 2007.
45. Study of RSD1235 in patients with atrial fibrillation (NCT00281554). ClinicalTrials.gov Web site, February 15, 2007.
46. Study of RSD1235-SR for the prevention of atrial fibrillation/atrial flutter recurrence (NCT00267930). ClinicalTrials.gov Web site, February 15, 2007.
47. Cardiome announces positive phase 2a results for oral RSD1235. Cardiome Pharma Press Release, September 13, 2006.